InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（13 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
13
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Parmar Kush, 董事. Insider active across 4 companies, notably Rallybio Corp. Cumulatively, 16 disclosures have been published. Split: 0 buy · 13 sells. Total volume traded: €11.2m. History available since 16 November 2021. The latest transaction was disclosed on 6 August 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Parmar Kush
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报16 总计
10,494 股@ US$7.000.027% mcap1.8% 占其流量Common StockSEC:0001664281-26-000004:0
52,317 股@ US$6.850.13% mcap8.6% 占其流量Common StockSEC:0001664281-26-000004:1
92,444 股@ US$7.000.24% mcap15.5% 占其流量Common StockSEC:0001664281-26-000004:2
114,756 股@ US$6.930.30% mcap25.9% 占其流量Common StockSEC:0001664281-26-000002:0
1,718 股@ US$6.850.0045% mcap0.4% 占其流量Common StockSEC:0001664281-26-000002:1
200,000 股@ US$8.8076.8% 占其流量Common StockSEC:0001664281-25-000003:0
20,065 股@ US$7.50228.0% 占其流量Common StockSEC:0001415889-25-019680:0
55,735 股@ US$6.91100.0% 占其流量Common StockSEC:0001415889-25-018824:0
100,000 股@ US$8.2013.0% 占其流量Common StockSEC:0001209191-23-017538:0
3,153,333 股Common StockSEC:0001104659-22-124136:0
99,671 股@ US$12.5026.8% 占其流量Common StockSEC:0001209191-22-034860:0
66,447 股@ US$13.0018.7% 占其流量Common StockSEC:0001209191-22-031969:0
139,539 股@ US$13.0536.8% 占其流量Common StockSEC:0001209191-22-008579:0
238,870 股@ US$15.30100.0% 占其流量Common StockSEC:0001209191-21-065656:0
318,616 股Common StockSEC:0001104659-21-134772:0
2,784,626 股Common StockSEC:0001209191-21-049823:0
16 条申报中的 16 条
About Parmar Kush
PARMAR KUSH is Administrateur and has 13 filings in total. Across the 13 sampled recent filings, all are sales, for total sell volume of EUR 10216254 between 2021-08-04 and 2026-08-03. The companies mentioned in these filings are Entrada Therapeutics, Inc., Rallybio Corp, Akouos, Inc., and Vor Biopharma Inc.
